Comparative Pharmacology
Head-to-head clinical analysis: HUMATIN versus NEOMYCIN SULFATE DEXAMETHASONE SODIUM PHOSPHATE.
Head-to-head clinical analysis: HUMATIN versus NEOMYCIN SULFATE DEXAMETHASONE SODIUM PHOSPHATE.
HUMATIN vs NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. Dexamethasone is a corticosteroid that induces phospholipase A2 inhibitory proteins, thereby suppressing prostaglandin and leukotriene synthesis, reducing inflammation.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
Ophthalmic: 1-2 drops of the solution or small amount of the ointment (approximately 1/2 inch into the conjunctival sac) every 3-4 hours, or more frequently if needed. Otic: 4 drops into the affected ear 3-4 times daily.
None Documented
None Documented
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Neomycin: terminal half-life ~2-3 hours after oral absorption (negligible systemic absorption); in renal impairment, half-life can extend to 12-24 hours. Dexamethasone: terminal half-life ~36-54 hours (mean ~48 hours) in adults.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Neomycin is primarily excreted unchanged in feces (~97%) after oral administration, with about 1% absorbed and renally excreted. Dexamethasone is metabolized in liver and excreted renally (~65% as metabolites, 2-5% unchanged) and in feces (~20%).
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic